Zenas BioPharma公司公布了其候选药物Obexelimab用于治疗免疫球蛋白G4相关疾病（IgG4-RD）的关键性3期INDIGO试验的完整数据。这一重要临床研究成果实现了双重发布：既在欧洲抗风湿病联盟2026年大会上进行了同步展示，也同时刊登在权威的《新英格兰医学杂志》上。
该注册性3期试验达到了其主要终点和所有关键的次要终点，数据显示Obexelimab治疗为IgG4-RD患者带来了具有统计学意义和临床意义的显著改善。这一积极结果标志着该药物在应对这一慢性、免疫介导的纤维炎症性疾病方面迈出了关键一步，为该药的后续监管提交奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.